Nelfinavir - major trial results at retroviruses conference.

  • Published 1997 in AIDS treatment news

Abstract

Nelfinavir (Viracept) is expected to be approved soon by the Food and Drug Administration (FDA). This fourth protease inhibitor appears to have fewer side effects, a different resistance profile, and offers new options for combination therapy. Results from all trials by the manufacturer, Agouron, showed statistically significant improvements in CD4 counts… (More)

Topics

Cite this paper

@article{1997NelfinavirM, title={Nelfinavir - major trial results at retroviruses conference.}, author={}, journal={AIDS treatment news}, year={1997}, volume={No 265}, pages={3-4} }